Why Bayer’s Big Monsanto Bid Has Fallen Flat
One problem with conglomerates is that there is something to dislike for everyone. Bayer’s bid to buy U.S. seeds and pesticides company Monsanto risks suffering the same affliction, at least as far as its shareholders are concerned.
This remains true, even if details released Monday of the $62 billion offer including debt look better than expected. Bayer, whose business spans pharmaceuticals, crop sciences and consumer health, seems to be shoveling as much low-cost debt as possible into the all-cash deal, which helped it promise...